Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
Leonard, John P.
Kaminski, Mark S.
Braziel, Rita M.
Spier, Catherine M.
Gopal, Ajay K.
Maloney, David G.
Cheson, Bruce D.
Smith, Sonali M.
Fisher, Richard I.
Friedberg, Jonathan W.
Press, Oliver W.
MetadataShow full item record
PublisherAMER SOC CLINICAL ONCOLOGY
CitationContinued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016 Mazyar Shadman, Hongli Li, Lisa Rimsza, John P. Leonard, Mark S. Kaminski, Rita M. Braziel, Catherine M. Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker Dakhil, Michael LeBlanc, Sonali M. Smith, Richard I. Fisher, Jonathan W. Friedberg, and Oliver W. Press Journal of Clinical Oncology 2018 36:7, 697-703
JournalJOURNAL OF CLINICAL ONCOLOGY
Rights© 2018 by American Society of Clinical Oncology
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractPurpose & para;& para;SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL.& para;& para;Patients and Methods & para;& para;Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, Ill, or IV) of any pathologic grade (1, 2, or 3) were eligible.& para;& para;Results & para;& para;After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81 %; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02).& para;& para;Conclusion & para;& para;Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority. (C) 2018 by American Society of Clinical Oncology
Note6 month embargo; published online: 22 January 2018
VersionFinal published version
SponsorsNational Cancer Institute, National Institutes of Health [CA180888, CA180819, CA180821, CA189953, CA180801, CA189808, CA189957, CA189952, CA189822, CA189872, CA189853, CA189804, CA180818, CA189860, CA189848, CA189972, CA180828, CA189997, CA180846, CA189858, CA180835]; GlaxoSmithKline
- Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
- Authors: Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI
- Issue date: 2013 Jan 20
- R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
- Authors: Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW
- Issue date: 2018 Mar
- Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
- Authors: Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K, JCOG0203 Collaborators.
- Issue date: 2018 Nov
- Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
- Authors: Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group.
- Issue date: 2006 Sep 1
- A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
- Authors: Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI
- Issue date: 2003 Sep 1